

PRECEPTORSHIP PROGRAMME

Colorectal Cancer

**ESMO
PRECEPTORSHIP**

**MEXICO CITY MEXICO
24-25 MARCH 2022**

Multidisciplinary management, standards of care, therapeutic targets and future perspectives.

Chairs:

Dirk Arnold, Germany
Rachel Riechelmann, Brazil
Erika Ruíz-García, Mexico

ESMO PRECEPTORSHIP PROGRAMME

COLORECTAL CANCER

Multidisciplinary management, standards of care
and future perspectives

Mexico City, Mexico
24-25 March 2022

CO-CHAIRS: Dirk Arnold, Germany
Rachel Riechelmann, Brazil
Erika Ruíz-García, Mexico

SPEAKERS: Horacio Astudillo, Mexico
David Huitzil, Mexico
Juan Manuel O'Connor, Argentina
Lino Silva, Mexico
Laura Torrecillas, Mexico
Itzel Vela, Mexico

LEARNING OBJECTIVES

- To learn about best clinical practice in the multidisciplinary management of colorectal cancer in the adjuvant and metastatic settings
- To understand the importance of pathology and histo-prognostic factors
- To learn about the management of patients after progression, side-effects of treatments and in special situations

ACCREDITATION

The programme of this event has been accredited with **10 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



Thursday, 24 March 2022

08:30-08:45 15'	Welcome and introduction	Chairs: Dirk Arnold, DE Erika Ruíz-Garcia, MX
08:45-10:05 80'	SESSION 1 Early colorectal cancer	Chairs: Dirk Arnold, DE Laura Torrecillas, MX David Huitzil, MX
20'	The point of view of the pathologist: - Quality and rules of a good pathology report - Histo-pathological relevant factors	Lino Silva, MX
20'	Managing rectal cancer: Patient selection, and multimodal treatment strategies, and goals: From "limited" to "total".	Dirk Arnold, DE
20'	The role of systemic therapy in rectal cancer: (Neo)adjuvant procedures. The view of a Medical Oncologist	Laura Torrecillas, MX
20'	Optimal surgery in rectal cancer: Why meso-rectal surgical resection is better? Minimal invasive surgery is safe in rectum?	Itzel Vela, MX
10:05-10:35	Coffee break	
10:35-12:15 100'	SESSION 2 Metastatic colorectal cancer: About decision making	Chairs: Erika Ruíz-Garcia, MX Rachel Riechelmann, BR
30'	How to select the best 1 st line treatment?	Rachel Riechelmann, BR
20'	Oligometastatic colorectal cancer: Understanding disease basics and treatment decisions	Dirk Arnold, DE
20'	Oligometastatic colorectal cancer: How to optimally treat limited metastatic disease?	David Huitzil, MX
30'	Clinical cases: An expert real case from speakers	All chairs
12:15-13:30	Lunch	
13:30-15:25 115'	SESSION 3 Special clinical situations	Chairs: Juan Manuel O'Connor, AR Rachel Riechelmann, BR
20'	Treatment of patient progressing after 1 st line and beyond	Rachel Riechelmann, BR
30'	Molecular subtypes of advanced colon cancer: RAS- and BRAF mutant, HER2, and others: What can we do?	Erika Ruíz-Garcia, MX
20'	Circulating tumour DNA (ctDNA) in colorectal cancer: Status quo further perspectives	Dirk Arnold, DE
45'	Participants clinical case discussion (3x15')	Faculty
15:25-16:00	Coffee break	

16:00-18:20 140'	SESSION 4 Adjuvant settings of colorectal cancer	Chairs: Erika Ruíz-Garcia, MX Dirk Arnold, DE
30'	Molecular markers in localized disease	Horacio Astudillo, MX
15'	Adjuvant treatment strategies for stage II colon cancer: Tailoring the benefit	Juan Manuel O'Connor, AR
15'	Adjuvant Chemotherapy for stage III colon cancer: To whom, and how?	Juan Manuel O'Connor, AR
20'	Early onset colorectal cancer and the implications in clinical practice	Erika Ruíz-Garcia, MX
60'	Participants clinical case discussion (4x15'): Localized, colon and rectal cancer	Faculty
20:30	Dinner	

Friday, 25 March 2022

08:30-10:40 130'	SESSION 5 Metastatic colorectal cancer: Special clinical cases	Chairs: Dirk Arnold, DE Erika Ruíz-Garcia, MX
15'	Maintenance treatment: What to do, after induction?	Dirk Arnold, DE
30'	Immunotherapy in colorectal cancer: Where are we? And how will this field evolve?	Rachel Riechelmann, BR
25'	Treatment of side effects	Erika Ruíz-Garcia, MX
60'	Participants clinical case discussion (4x15')	Faculty
10:40-10:50 10'	Closing remarks	Chairs: Dirk Arnold, DE Erika Ruíz-Garcia, MX Rachel Riechelmann, BR
10'	Closing and final remarks	Dirk Arnold, DE Erika Ruíz-Garcia, MX Rachel Riechelmann, BR

Note: Each 15-minute slot for clinical case discussion includes 7' case presentation and 8' Q&A / panel discussion